ArticleJournal of inflammation research2026
Mucosal Involvement in Bullous Pemphigoid: Severity Indicator and Associated Clinical Features from a Retrospective Cohort Study.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disorder. Although mucosal involvement is uncommon, it may indicate a more severe clinical phenotype. This study evaluated the prevalence and clinical features associated with mucosal involvement in BP. Patients and Methods: This retrospective cohort study included 265 patients with BP diagnosed at Peking Union Medical College Hospital between January 2013 and May 2022. Clinical, laboratory, immunological, and treatment-related characteristics were compared between patients with and without mucosal involvement. Logistic regression analyses were performed to identify factors associated with mucosal involvement, and model performance was assessed using receiver operating characteristic analysis. Results: Seventy-one patients (26.8%) had mucosal involvement, most commonly affecting the oral mucosa, followed by genital and ocular sites. Compared with patients without mucosal lesions, those with mucosal involvement were younger at disease onset, more frequently had a history of malignancy, and showed a more severe clinical phenotype, including higher hospitalization rates, more infections within 1 year, higher corticosteroid requirements, higher BPDAI scores, and more frequent head/neck and hands/feet involvement. Indirect immunofluorescence seropositivity and peripheral eosinophilia were less frequent in patients with mucosal involvement. In multivariate analysis, head/neck involvement (adjusted OR 8.276, 95% CI 2.211-30.977), hands/feet involvement (adjusted OR 34.559, 95% CI 8.191-145.805), and higher BPDAI score (adjusted OR 1.055, 95% CI 1.020-1.091) were independently associated with mucosal involvement, whereas peripheral eosinophilia was inversely associated (adjusted OR 0.027, 95% CI 0.005-0.148). The model demonstrated excellent apparent discrimination (AUC 0.937). Conclusion: Mucosal involvement in BP is associated with a more severe clinical phenotype. Head/neck and acral involvement, higher BPDAI scores, and a lower frequency of peripheral eosinophilia may serve as practical clinical indicators for identifying patients who require closer mucosal assessment and more intensive monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.